Editing AUA: Overactive Bladder (2019) (section)

==== β 3-adrenoceptor agonists: Mirabegron ====
*<span style="color:#ff0000">'''Similar efficacy profile to the anti-muscarinics and a relatively lower adverse event profile.'''</span>
**Lower incidence of bothersome adverse events may inform the selection of medications for patients who already present with dry mouth (e.g., secondary to Sjogren's syndrome) and/or constipation or for patients who experience efficacy from the anti-muscarinics but cannot tolerate these adverse events.

===== Efficacy =====
*Significant symptom reductions for voids per day and incontinence episodes per day
*Improvements in UUI, urgency episodes, and QOL measures also occur but were not as consistently statistically significant. 
*Among studies with an active control group administered tolterodine ER 4 mg/daily, mirabegron generally performed similarly to tolterodine. Higher doses of mirabegron did not produce greater effects.

===== Adverse events =====

#<span style="color:#ff0000">'''Increased heart rate'''</span>
#<span style="color:#ff0000">'''Increased blood pressure'''</span>
#*Changes in blood pressure and pulse rate are usually minor
#<span style="color:#ff0000">'''Constipation'''</span>
#*May produce lower/similar rates of constipation than some of the anti-muscarinics, except for solifenacin (5 mg and 10 mg), fesoterodine (8 mg) and trospium (60 mg), all of which had a higher risk of constipation.